Precision Medicine in Inflammatory Bowel Disease: Individualizing the Use of Biologics and Small Molecule Therapies

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2023 Mar 27

PMID 36970587

Authors

Eric Cheah

James Guoxian Huang

Affiliations

Soon will be listed here.

Abstract

The advent of biologics and small molecules in inflammatory bowel disease (IBD) has marked a significant turning point in the prognosis of IBD, decreasing the rates of corticosteroid dependence, hospitalizations and improving overall quality of life. The introduction of biosimilars has also increased affordability and enhanced access to these otherwise costly targeted therapies. Biologics do not yet represent a complete panacea: A subset of patients do not respond to first-line anti-tumor necrosis factor (TNF)-alpha agents or may subsequently demonstrate a secondary loss of response. Patients who fail to respond to anti-TNF agents typically have a poorer response rate to second-line biologics. It is uncertain which patient would benefit from a different sequencing of biologics or even a combination of biologic agents. The introduction of newer classes of biologics and small molecules may provide alternative therapeutic targets for patients with refractory disease. This review examines the therapeutic ceiling in current treatment strategies of IBD and the potential paradigm shifts in the future.

Citing Articles

Navigating new horizons in inflammatory bowel disease: Integrative approaches and innovations.

Zhang S World J Gastroenterol. 2024; 30(41):4411-4416.

PMID: 39534414 PMC: 11551671. DOI: 10.3748/wjg.v30.i41.4411.

Antibodies Targeting the Tumor Necrosis Factor-Like Ligand 1A in Inflammatory Bowel Disease: A New Kid on the (Biologics) Block?.

Schweckendiek D, Rogler G Digestion. 2024; 105(6):411-418.

PMID: 39068930 PMC: 11633870. DOI: 10.1159/000540421.

Defining management strategies for acute severe ulcerative colitis using predictive models: a simulation-modeling study.

Con D, De Cruz P Intest Res. 2024; 22(4):439-452.

PMID: 38712360 PMC: 11534451. DOI: 10.5217/ir.2023.00175.

Is tumor necrosis factor-α monoclonal therapy with proactive therapeutic drug monitoring optimized for inflammatory bowel disease? Network meta-analysis.

Zheng F, Yang K, Min W, Li X, Xing Y, Wang S World J Gastrointest Surg. 2024; 16(2):571-584.

PMID: 38463352 PMC: 10921189. DOI: 10.4240/wjgs.v16.i2.571.

Editor-in-Chief articles of choice and comments at the year-end of 2023.

Tarnawski A World J Gastroenterol. 2024; 30(1):1-8.

PMID: 38293322 PMC: 10823905. DOI: 10.3748/wjg.v30.i1.1.

References

Sands B, Chen J, Feagan B, Penney M, Rees W, Danese S . Efficacy and Safety of MEDI2070, an Antibody Against Interleukin 23, in Patients With Moderate to Severe Crohn's Disease: A Phase 2a Study. Gastroenterology. 2017; 153(1):77-86.e6. DOI: 10.1053/j.gastro.2017.03.049. View

Singh S, Murad M, Fumery M, Dulai P, Sandborn W . First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis. Clin Gastroenterol Hepatol. 2020; 18(10):2179-2191.e6. PMC: 8022894. DOI: 10.1016/j.cgh.2020.01.008. View

Bossuyt P, Dreesen E, Rimola J, Devuysere S, De Bruecker Y, Vanslembrouck R . Infliximab Exposure Associates With Radiologic Evidence of Healing in Patients With Crohn's Disease. Clin Gastroenterol Hepatol. 2020; 19(5):947-954.e2. DOI: 10.1016/j.cgh.2020.04.052. View

Adedokun O, Sandborn W, Feagan B, Rutgeerts P, Xu Z, Marano C . Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis. Gastroenterology. 2014; 147(6):1296-1307.e5. DOI: 10.1053/j.gastro.2014.08.035. View

Schoepfer A, Beglinger C, Straumann A, Safroneeva E, Romero Y, Armstrong D . Fecal calprotectin more accurately reflects endoscopic activity of ulcerative colitis than the Lichtiger Index, C-reactive protein, platelets, hemoglobin, and blood leukocytes. Inflamm Bowel Dis. 2013; 19(2):332-41. DOI: 10.1097/MIB.0b013e3182810066. View

Biasci D, Lee J, Noor N, Pombal D, Hou M, Lewis N . A blood-based prognostic biomarker in IBD. Gut. 2019; 68(8):1386-1395. PMC: 6691955. DOI: 10.1136/gutjnl-2019-318343. View

Kwapisz L, Raffals L, Bruining D, Pardi D, Tremaine W, Kane S . Combination Biologic Therapy in Inflammatory Bowel Disease: Experience From a Tertiary Care Center. Clin Gastroenterol Hepatol. 2020; 19(3):616-617. DOI: 10.1016/j.cgh.2020.02.017. View

Davidov Y, Ungar B, Bar-Yoseph H, Carter D, Haj-Natour O, Yavzori M . Association of Induction Infliximab Levels With Clinical Response in Perianal Crohn's Disease. J Crohns Colitis. 2017; 11(5):549-555. DOI: 10.1093/ecco-jcc/jjw182. View

. Efficacy and Safety of Combination Induction Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis: Results Through Week 12 of a Phase 2a Randomized, Double-Blind, Active-Controlled,.... Gastroenterol Hepatol (N Y). 2022; 18(4 Suppl 1):9-10. PMC: 9122068. View

10.

Adedokun O, Xu Z, Gasink C, Jacobstein D, Szapary P, Johanns J . Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease. Gastroenterology. 2018; 154(6):1660-1671. DOI: 10.1053/j.gastro.2018.01.043. View

11.

Stalgis C, Deepak P, Mehandru S, Colombel J . Rational Combination Therapy to Overcome the Plateau of Drug Efficacy in Inflammatory Bowel Disease. Gastroenterology. 2021; 161(2):394-399. DOI: 10.1053/j.gastro.2021.04.068. View

12.

Verstockt B, Verstockt S, Blevi H, Cleynen I, de Bruyn M, Van Assche G . TREM-1, the ideal predictive biomarker for endoscopic healing in anti-TNF-treated Crohn's disease patients?. Gut. 2018; 68(8):1531-1533. DOI: 10.1136/gutjnl-2018-316845. View

13.

Glassner K, Oglat A, Duran A, Koduru P, Perry C, Wilhite A . The use of combination biological or small molecule therapy in inflammatory bowel disease: A retrospective cohort study. J Dig Dis. 2020; 21(5):264-271. DOI: 10.1111/1751-2980.12867. View

14.

Papamichael K, Vande Casteele N, Jeyarajah J, Jairath V, Osterman M, Cheifetz A . Higher Postinduction Infliximab Concentrations Are Associated With Improved Clinical Outcomes in Fistulizing Crohn's Disease: An ACCENT-II Post Hoc Analysis. Am J Gastroenterol. 2021; 116(5):1007-1014. PMC: 8095681. DOI: 10.14309/ajg.0000000000001111. View

15.

Zhang Z, Li C, Zhao X, Lv C, He Q, Lei S . Anti-Saccharomyces cerevisiae antibodies associate with phenotypes and higher risk for surgery in Crohn's disease: a meta-analysis. Dig Dis Sci. 2012; 57(11):2944-54. DOI: 10.1007/s10620-012-2244-y. View

16.

Olbjorn C, Rove J, Jahnsen J . Combination of Biological Agents in Moderate to Severe Pediatric Inflammatory Bowel Disease: A Case Series and Review of the Literature. Paediatr Drugs. 2020; 22(4):409-416. PMC: 7383034. DOI: 10.1007/s40272-020-00396-1. View

17.

Dreesen E, Verstockt B, Bian S, de Bruyn M, Compernolle G, Tops S . Evidence to Support Monitoring of Vedolizumab Trough Concentrations in Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2018; 16(12):1937-1946.e8. DOI: 10.1016/j.cgh.2018.04.040. View

18.

Choung R, Princen F, Stockfisch T, Torres J, Maue A, Porter C . Serologic microbial associated markers can predict Crohn's disease behaviour years before disease diagnosis. Aliment Pharmacol Ther. 2016; 43(12):1300-10. DOI: 10.1111/apt.13641. View

19.

Papamichael K, Jairath V, Zou G, Cohen B, Ritter T, Sands B . Proactive infliximab optimisation using a pharmacokinetic dashboard versus standard of care in patients with Crohn's disease: study protocol for a randomised, controlled, multicentre, open-label study (the OPTIMIZE trial). BMJ Open. 2022; 12(4):e057656. PMC: 8977745. DOI: 10.1136/bmjopen-2021-057656. View

20.

Sands B, Irving P, Hoops T, Izanec J, Gao L, Gasink C . Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial. Lancet. 2022; 399(10342):2200-2211. DOI: 10.1016/S0140-6736(22)00688-2. View